Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Natus Medical $1.2 billion acquisition by ArchiMed
We are advising Natus Medical on the transaction
Charles River Laboratories $295 million acquisition of Explora BioLabs Holdings
We advised Charles River on the transaction
Novo Nordisk insulin pricing litigation victory
We prevailed in having the complaint dismissed with prejudice
Owens & Minor $600 million notes offering
The high-yield notes are due 2030
AN2 Therapeutics $69 million IPO
The shares are listed on the Nasdaq Global Select Market
Roche Holdings $5 billion notes offering
We advised Roche on the Rule 144A / Regulation S offering comprising five tranches of notes
Denali $400 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
$12.6 billion financing for investor group acquisition of a software company
We advised the debt and preferred equity financing sources on the transaction
Signify Health $250 million acquisition of Caravan Health
We are advising Signify Health on the transaction
Silver Spike Acquisition Corp. II combination with Eleusis
We are advising the SPAC on the transaction